Hot Features
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orp... Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is headquartered in Fitzroy, Australia. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.005 | -2.32558139535 | 0.215 | 0.22 | 0.19 | 3026842 | 0.19963534 | DE |
| 4 | 0.025 | 13.5135135135 | 0.185 | 0.25 | 0.1575 | 3627608 | 0.19484453 | DE |
| 12 | -0.11 | -34.375 | 0.32 | 0.42 | 0.1575 | 2830363 | 0.2208818 | DE |
| 26 | -0.34 | -61.8181818182 | 0.55 | 0.57 | 0.1575 | 1861167 | 0.28474969 | DE |
| 52 | -0.38 | -64.406779661 | 0.59 | 0.665 | 0.1575 | 1620348 | 0.38943553 | DE |
| 156 | 0.15 | 250 | 0.06 | 0.785 | 0.06 | 2575508 | 0.37655917 | DE |
| 260 | 0.005 | 2.43902439024 | 0.205 | 0.785 | 0.052 | 1753724 | 0.35770746 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.